Camlin Fine Sciences share price today

Camlin Fine Sciences Ltd's share price was ₹84.05 at the close on 30 October 2026. It has been falling for 51 weeks. That is 31.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹80 and ₹196, and at that close it sat 3% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Camlin Fine Sciences Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 14 weeks running.

Over the last 11 years the share price moved −9% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 31 July 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: lowest operating margin in 15 quarters, indian funds and insurers (DIIs) cut their stake for 3 quarters in a row and highest quarterly revenue in 15 quarters.

1. Lowest operating margin in 15 quarters

   Operating margin was 1.8% in the June 2026 quarter, against 5% a year earlier.

   Why: Margins fell because raw materials cost more, shipping took longer and cost more, and the company could not pass all the higher costs to customers.

   Next results: check whether Aroma and Performance Chemicals turn profitable in Q2 and whether the overall margin gets back to double digits in Q3.

   From the earnings call on 11 Aug 2026.

2. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row

   From 7.8% to 5.3% of the company by the September 2026 quarter.

3. Highest quarterly revenue in 15 quarters

   Revenue of ₹520 crore in the June 2026 quarter is the highest of the last 15 quarters.

   Why: Revenue hit a record because demand for blends stayed strong, especially in America.

   Next results: check whether blends sales grow by the planned 25 to 30 percent this year.

   From the earnings call on 11 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Camlin Fine Sciences reported revenue of ₹520 crore, up 27.5% from ₹408 crore a year earlier, and a loss of ₹34.0 crore.

Camlin Fine Sciences results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Camlin Fine Sciences' management discussed these results on a call held on 11 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Camlin Fine Sciences closed at ₹84.05 on 30 October 2026, down 57.1% from ₹195.90 a year earlier (31 October 2025) and down 47.9% over five years. Its highest weekly close since March 2016 was ₹327.53 on 27 June 2025.

Camlin Fine Sciences share price: then and now

Weekly closing prices. Each change is the move from that price to the 30 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes.

562 weekly closes from 11 March 2016 to 30 October 2026.

30 Oct 2026: Camlin Fine Sciences closed at ₹84.05, up 4.6% on the week and down 7.8% on the month. 11 Aug 2026: Camlin Fine Sciences held its results call for April to June 2026. Management guided: FY27 revenue ₹2,200-2,300 crore and operating profit ₹220-230 crore at 10-11% margin; average operating profit around ₹70 crore across the next three quarters.

Earlier

• Results for April to June 2026: Revenue up 27.5% on a year earlier.

Camlin Fine Sciences has paid no dividend on the NSE since 1 April 2021, the start of the period we checked.

Not in its latest year. Camlin Fine Sciences Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 3 of its last 13 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 11 August 2026, Camlin Fine Sciences' management guided: FY27 revenue ₹2,200-2,300 crore and operating profit ₹220-230 crore at 10-11% margin; average operating profit around ₹70 crore across the next three quarters.

“Obviously, the prolonged war situation can result in different outcomes, but if prices stabilize at their current levels, we should be looking at EBITDA in the range of 10-12% going forward.”Santosh Parab, CFO, on the call for April to June 2026

What management guided

• FY28 operating margin 12-14% after normalization, supported by stable fixed costs.
• Specialty Ingredients blends growth planned at 25-30% in FY27, with 20% described as the minimum.
• Vanillin production approximately 3,000 tons in FY27; Q2 sales 500-600 metric tons and Q3 production and sales above 1,000 metric tons.
• Aroma and Performance Chemicals to reach positive operating profit in Q2; consolidated operating margin to return to double digits in Q3.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 11 August 2026.

When Camlin Fine Sciences reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Q2-to-Q3 consolidated margin recovery - check segment turns, raw-material pass-through and the planned normalization trajectory.

Camlin Fine Sciences is on one of our India lists: Penny stocks.

Camlin Fine Sciences Ltd posted a net loss of ₹34.0 Cr in the Jun 2026 quarter. Full-year FY26 profit was ₹24.0 Cr. Over 10 years profit has grown −4.0% a year on average. That loss is 6.5% of the quarter's revenue. The same quarter a year earlier lost ₹11.0 Cr. 10 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Camlin Fine Sciences Ltd reported ₹520 Cr of revenue in the Jun 2026 quarter, +27.5% on the same quarter a year earlier. Over 10 years it has grown 13.4% a year on average. The last full year, FY26, came in at ₹1,723 Cr. The last four reported quarters add to ₹1,846 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹1,723 Cr, +5.8% on the year before.

Recent pace: the last four quarters grew +9.6% on average, against 13.4% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +9.4%, against +9.1% a year over the last 8 quarters (stabilising).

Camlin Fine Sciences Ltd's operating margin was 1.8% in the Jun 2026 quarter, 3.2 percentage points lower than the same quarter a year ago. Across 13 years it has been between 2.2% and 19.0%. The latest quarter is below every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −3.2 percentage points on the year while gross margin changed −3.4 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 224% of Camlin Fine Sciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹82.0 Cr of operating cash against ₹24.0 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹277 Cr of spending on assets, free cash was −₹195 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 224% of profit came in as cash: the cash cycle got 106 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Camlin Fine Sciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 78 days in FY26, down from 184 days in FY21. It spent ₹207 Cr on assets over the last 3 years. Customers take 79 days to pay, and stock sits for 199 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹1,723 Cr, each day of that cycle ties up about ₹4.7 Cr, so roughly ₹368 Cr is tied up in the business at any time.

FY26: customers took 79 days to pay and stock sat for 199 days, about 6.5 months of sales sitting as stock, for a full cycle of 78 days, shorter than FY21's 184.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 199 days. Customers pay about 79 days after that. Suppliers are paid at 200 days. Together that makes the 78-day cycle.

Spending on assets: ₹207 Cr over the last 3 years, against ₹188 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹33.0 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Camlin Fine Sciences Ltd's P/E is 66.7×, near the high end of its own history: higher than 75% of past readings. Its usual P/E (the middle reading) is 47.9×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.